160 related articles for article (PubMed ID: 16809800)
1. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.
Roskos LK; Lum P; Lockbaum P; Schwab G; Yang BB
J Clin Pharmacol; 2006 Jul; 46(7):747-57. PubMed ID: 16809800
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function.
Yang BB; Kido A; Salfi M; Swan S; Sullivan JT
J Clin Pharmacol; 2008 Sep; 48(9):1025-31. PubMed ID: 18524995
[TBL] [Abstract][Full Text] [Related]
3. Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.
Krzyzanski W; Wiczling P; Lowe P; Pigeolet E; Fink M; Berghout A; Balser S
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):101S-112S. PubMed ID: 20881223
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
[TBL] [Abstract][Full Text] [Related]
6. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques.
Farese AM; Yang BB; Roskos L; Stead RB; MacVittie TJ
Bone Marrow Transplant; 2003 Aug; 32(4):399-404. PubMed ID: 12900776
[TBL] [Abstract][Full Text] [Related]
10. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.
Yang BB; Kido A; Shibata A
Pharmacotherapy; 2007 Oct; 27(10):1387-93. PubMed ID: 17896894
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
[TBL] [Abstract][Full Text] [Related]
12. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
Brekkan A; Lopez-Lazaro L; Yngman G; Plan EL; Acharya C; Hooker AC; Kankanwadi S; Karlsson MO
AAPS J; 2018 Aug; 20(5):91. PubMed ID: 30112626
[TBL] [Abstract][Full Text] [Related]
13. Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy.
Invernizzi R; Grasso D; Travaglino E; Benatti C; Collovà E; Manzoni M; Livraghi L; Danova M; Riccardi A
Oncology; 2008; 75(3-4):237-44. PubMed ID: 18854646
[TBL] [Abstract][Full Text] [Related]
14. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Singh I; Attrey A; Garg A; Patel R; Jose V
Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
Willis F; Woll P; Theti D; Jamali H; Bacon P; Baker N; Pettengell R
Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
[TBL] [Abstract][Full Text] [Related]
19. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
Desai K; Catalano T; Rai G; Misra P; Shah N
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
Singh I; Patel A; Patel R; Jose V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
